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Kissing cousins exchange CLIP
HLA-DM, a recent addition to the immunoglobulin family, is structurally
most like class II molecules of the MHC. DM facilitates exchange of CLIP, a
temporary filler of the groove of class II molecules, for antigenic peptides.
A central event in the development of a specific immune
response is recognition by the T-cell receptor of an
antigenic peptide bound within the groove of a class I or
class II molecule of the major histocompatibility complex
(MHC) [1]. Class I molecules handle peptides from
proteins synthesized within the cell, such as viral pro-
teins, which they present to lymphocytes bearing the
cell-surface marker CD8. Class I-binding peptides are
generated by a multi-component protease, the protea-
some, and are loaded into the groove of the class I mol-
ecule after translocation into the endoplasmic reticulum
(ER). Class II molecules, on the other hand, are respon-
sible for presenting peptides derived from extracellular
pathogens to the CD4-bearing subset of T cells.
shown that the CLIP region is both necessary and
sufficient for the blocking and stabilizing effects of intact
Ii on MHC class II molecules.
Two observations suggest that the binding of CLIP to
HLA-DR is different from the binding of antigenic pep-
tides. First, certain antibodies (such as the monoclonal
16.23) that normally recognize cell-surface class 1I
molecules are unable to bind the 1-CLIP complex.
Second, although mature class II-peptide complexes are
characteristically stable in the detergent SDS, most
The human class II molecules - HLA-DP, -DQ and
-DR, of which HLA-DR is the prototype (Fig. 1) - are
heterodimers of two immunoglobulin (Ig) superfamily
protein chains, ax and 13, the genes for which reside
together in the MHC. Upon synthesis, class II a13 het-
erodimers associate with the invariant chain, Ii, a type II
(inverted) membrane protein with which they are expor-
ted from the ER in a nonameric complex. Unlike MHC
class I molecules, newly synthesized class II molecules do
not follow the constitutive secretory pathway. Instead, to
allow them to capture peptides from external sources,
they are guided by targeting signals contained in the
cytoplasmic tail of Ii onto a pathway that intersects that
of endocytic traffic (Fig. 2). This journey to the cell sur-
face takes several hours, during which time Ii is degraded
and removed from the class II molecule, which is in turn
loaded with peptide in an acidic compartment. Ii has
other important functions: it helps assembly of class II a
and chains and prevents their aggregation; it also blocks
the groove of class II a13 heterodimers, so preventing
binding of self peptides in the lumen of the ER.
A strong indication as to how Ii fulfils its blocking and
stabilizing roles is provided by mutant cell lines in which
the processing of antigens to be presented by class II mol-
ecules is faulty. Most of the class II molecules on the sur-
faces of these cells are bound not by the normal spectrum
of antigenic peptides but by a nested set of fragments that
span residues 81-105 of Ii and are known as CLIP (class
II-associated invariant chain peptides). The normal fate
of class II-bound Ii is to be attacked by proteases which
remove it in sections, systematically. CLIP is the smallest
fragment of Ii to be retained, and ua3-CLIP complexes
form a natural intermediate in class II maturation in vivo
[2]. Genetic truncation and deletion experiments have
Fig. 1. HLA-DM is a distant cousin of class I and class II
molecules of the MHC. Sequence comparisons show that DM
may have split from the primordial class I and class II sequences
early on in evolution; the protein structures are shown, highly
schematically, below the tree. DM is similar in arrangement to
other class II structures, except for the extra cysteine (C) residues
in the ul and 31 domains, the amino-acid sequences of which
are only weakly related to those of other HLA molecules. DM
has no recognizable CD4-binding site.
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Fig. 2. Behaviour of DR in DM+ and DM- cells. Peptides in the lumen of the ER are prevented from binding to class II by i. Ii and the a
and chains of the class II molecule form a nonameric complex, (1i) 3, for transport, held together by a 'trimerization' sequence in
the carboxy-terminal (luminal) region of Ii (see also Fig. 4). Destruction of the trimerization domain of i, at a later stage, as the nonamer
moves to the endocytic vesicles under the guidance of amino-terminal Ii signals, may be a key step in the process. DM has its own tar-
geting signal that may enable the molecule to be retrieved from the cell surface [181. DM may also interact with i in the ER. Degrada-
tion of endocytosed proteins takes place so that peptides are available to newly synthesized class II molecules as i is released. DM
accumulates in the MHC class II compartment (MIIC), where it is thought to catalyze peptide loading onto class II molecules; class II
molecules loaded with peptide move to the cell surface. There is evidence for cell-type-specific variations in this pathway, especially in
phagocytic cells, as well as for recycling of some class II molecules from the cell surface. The intravesicular pH through the class II
trafficking pathway decreases as it does in endocytosis, to lower than pH 5 in the MIIC.
CLIP-bound class II molecules dissociate in SDS into
their constituent a and 3 chains. Both findings point to a
structure for xot3-CLIP that is different from that adopted
by other class II-peptide complexes. In addition, attract-
ing and repelling forces between peptide side chains and
the polymorphic residues lining the class II peptide-bind-
ing groove result in the specificity of most peptides for a
limited range of class II allotypes; in contrast, CLIP binds
to most, if not all, class II allotypes. Although it seemed
possible that CLIP inhibits peptide binding indirectly, the
wide range of binding affinities exhibited by CLIP for
different class II molecules, and the allele-dependent
manner in which mutations introduced into synthetic
CLIP influence binding, has strongly favoured a model in
which CLIP occupies the groove [3,4]. Structure deter-
mination now confirms this [5].
Ghosh et al [5] have crystallized HLA-DR3 in an
ax3-CLIP complex and solved the structure to 2.75 A
resolution (Fig. 3). Remarkably, the o4-CLIP complex
has a structure almost indistinguishable from that of class
II with bound antigenic peptide (specifically, HLA-DR1
with a peptide from influenza virus haemagglutinin, HA
306-318). The CLIP is bound to HLA-DR3 in a confor-
mation and with a network of hydrogen bonds similar to
those in the HLA-DR1-HA complex, and with similar
side-chain-pocket interactions. The only conformational
difference between the DR3-CLIP and DR1-HA com-
plexes is in the second a-helical region of the DR3 3
chain (residues 65-74), which in the DR3-CLIP com-
plex has moved 1.5 A towards the peptide. This helical
section corresponds to the predicted epitope of the con-
formation-specific monoclonal antibody 16.23 [6], and
its displacement could provide an elegant explanation for
the recognition by the antibody of mature DR3-peptide
but not DR3-CLIP complexes [7].
The reason for the SDS-instability of class II-CLIP
complexes (including DR3-CLIP) is less clear. Certainly
it can no longer be attributed to any major difference
in the io3 portion of the structure. Nor is CLIP
more superficially bound: the conservation of hydrogen
bonds between the two complexes and the comparability
of solvent-accessible surfaces argue that, as predicted
from affinity measurements in vitro, DR3-CLIP and
DR1-HA complexes will have similar stabilities. In the
context of intact Ii, the residues spanned by the CLIP
fragment need not necessarily bind within the ot
groove nor with the conformation adopted by the iso-
lated peptide. But if they do, the deep interactions
demonstrated in the oaL-CLIP crystal structure could be
responsible for Ii-mediated stabilization of xa13 in much
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of CLIP from DR, as well as facilitating loading
with antigenic peptides. Incorporation of DR molecules
from wild-type cells into DM-containing membranes
accelerates peptide binding in vitro [15]. Membrane
reconstitution is not essential, however: immunoprecipi-
tated DM, purified soluble recombinant DM, and even
detergent-solubilized DM-containing membranes have
similar effects on DR molecules in solution [13,15]. All
three studies have demonstrated that, at acidic pH in
vitro, DM promotes the dissociation of CLIP from
a-CLIP complexes.
Fig. 3. Side view of CLIP within the HLA-DR3 peptide-binding site
[5]. (Graphic courtesy Partho Ghosh).
the same way as stability is conferred by the binding of
antigenic peptides.
Analysis of the same antigen-processing mutants that led
to the identification of CLIP as the universal class II-bind-
ing peptide has also identified a function for two novel
class II genes, HLA-DMA and HLA-DMB [8]: their
products are required for successful CLIP removal from,
and peptide loading onto, class II molecules [9,10].
Inspection of the DM protein sequences, as shown
schematically in Figure 1, reveals that the DM genes could
have split from the primordial class I/II sequences several
hundred million years ago, at around the time that class I
and class II diverged from each other. The DM u-2 and 32
domains are homologous to the membrane-proximal
domains of class I and II molecules; the al and 31
regions, which in DR form the peptide-binding groove,
contain little primary sequence homology but can be
modelled into a structure similar to the DR archetype
(C. Thorpe and P. Travers, personal communication).
Unlike the majority of class II heterodimers, little DM is
found at the cell surface. Instead, it accumulates together
with class II molecules in the specialized late endo-
somal/lysosomal MHC class II compartments (MIICs)
[11]. These membrane-bound vesicles co-migrate on
Percoll density gradients with compartments in which
immunostimulatory class II molecules first appear [12],
and they are the putative site of class II peptide loading.
Thus, DM is well placed for its apparent role in expe-
diting the association between antigenic peptide and class
II molecules.
So how does DM effect peptide exchange? Initially the
most attractive theories, given the molecule's class II-like
structure, proposed that DM might act either by binding
CLIP and removing it from the class II molecule to make
way for other peptides - the 'CLIP sink' model - or
by binding a range of peptides in endocytic vesicles and
bringing them to class II in a peptide-loading compart-
ment. Evidence from recent studies favours a different
scheme [13-15]. Rather than participating in a peptide-
shuttle type of mechanism, it seems that DM acts as a
catalyst which at low pH increases the dissociation rate
A requirement in vivo for DM in order to release Ii-
derived peptides from DR would account not only for
the persistence of DR-CLIP complexes in DM-negative
mutant cells, but also for the apparent DM-independence
of antigen presentation by the mouse allele I-Ak, which
stands out among class II molecules as having a remark-
ably low affinity for CLIP [4]. Much of the effect of
HLA-DM on peptide binding appears to be attributable
to DM-catalyzed CLIP release, but not all. Denzin and
Cresswell [14] compared the efficiencies with which
either DM or the detergent octylglucoside produces
peptide-loaded DR molecules from DR-CLIP com-
plexes in vitro. Although CLIP is released faster in the
presence of detergent, comparable peptide loading
requires 100-fold higher concentration of peptide. Thus,
DM appears to have a direct effect on peptide loading.
To date, there is no evidence that DM binds peptide; in
fact, under conditions in which it is clearly able to remove
CLIP from anx-CLIP complexes, no DM with bound
CLIP was detected [14]. To explain these data, it has been
proposed that DM interacts fleetingly with ota-CLIP
complexes, promoting CLIP release and then stabilizing a
peptide-receptive conformation adopted by the empty oa3
class II molecule [14]. Support for the notion that a physi-
cal interaction between the two molecules is required for
function comes from work on a DR molecule with a
proline-serine substitution at position 96 of the ax chain
(DR3Ser 96 ), which introduces an extra N-linked glycosy-
lation site [13]. The phenotype of the DR3Ser96 mutant in
vivo is similar to that of DR in DM-negative cells. In vitro,
the altered DR molecule is refractory to the effects of
DM on CLIP removal. A similar effect was produced by
the pre-incubation of a1-CLIP with an anti-CLIP anti-
body. It is reasonable to propose that both the bulky car-
bohydrate group on the mutant DR molecule and the
anti-CLIP antibody prevent interaction with DM. So far,
direct evidence for association between DR and DM has
been difficult to obtain. However, data from our labora-
tory show a non-covalent DM-DR interaction, under
conditions that approximate those of the appropriate
endosomal compartment (ES., C. Thomas, J. Neefjes and
J.T., unpublished observations).
It is odd that DM, the catalyst for DR peptide-loading, is
a molecule that shares a structural relationship with its
substrate yet does not appear to bind peptide. A
precedent can be found in the rat neonatal Fc receptor,
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Fig. 4. Speculative model of the role of DM in catalyzing peptide loading of DR. For details see text.
which has the primary structure of a typical class I
molecule, but its binding groove proved to be distorted
and empty [16]. A closer inspection of the sequence of
HLA-DM suggests that here too the putative groove may
be malformed, with bulky hydrophobic residues
obstructing it at one end. A speculative model for the
function of HLA-DM is therefore as follows. The class
II-Ii complex leaves the ER as a nonamer, and it is sig-
nificant that this complex is not a substrate for exchange
mediated by DM [14]. As the trimerization domain is in
the section of the Ii chain that is removed first, it seems
likely that the dissolution of the (Ii) 3 nonamer takes
place upon entering, or just before entering, the MIIC.
Which fragment of Ii is removed by DM in vivo is not
entirely clear. DM is certainly able to catalyze the disso-
ciation of fragments larger than CLIP in vitro [14], and it
is possible (as indicated in Fig. 4) that class II molecules
bound to these larger fragments serve as one, or possibly
even the principal, substrate for DM in vivo.
In this model, DM does not have to bind peptide itself in
order to effect peptide exchange on DR. Rather, as
mentioned above, the evidence points to a direct interac-
tion between the two MHC-encoded molecules. It is
necessary only to postulate a fleeting 'kiss' between DM
and DR (Fig. 4); in vitro, in the absence of peptide,
unoccupied class II o3 heterodimers become refractory
to peptide binding [17] and these may be stabilized by
association with DM. This interaction, by a mechanism
analogous to that by which an enzyme stabilizes a transi-
tion state, may account for both the release of CLIP and
the facilitation of peptide binding in vitro. Enzyme-sub-
strate binding is often of low affinity, and certainly the
association between DM and DR is difficult to demon-
strate. Although the structures of DR1-HA and
DR3-CLIP complexes are similar, the structure of the
empty ad intermediate is unknown. It is possible that a
change in conformation effected by peptide binding is
the trigger for the dissociation of DM, which is then free
to catalyze another round of peptide exchange.
One consequence of this model, and also one of the
most provocative features of DM-catalyzed peptide
dissociation in vitro, is that CLIP is not the only peptide
to be removed from DR [13]. The half-life of a
DR1-myelin basic protein complex was also shortened
by DM, and to a comparable extent to that of ot-CLIP
complexes. It has been suggested that the DM-catalyzed
dissociation of non-CLIP peptides in vivo serves an
important function [13]. By favouring the formation of a
subset of oa3-peptide complexes with long half-lives,
DM may be responsible for the observed selection of a
small number of immunodominant epitopes from the
array of available class II-binding peptides. Clearly, the
next step is to determine whether it is the affinity of
the peptide, a specific structural feature of the complex,
or some other characteristic of the class II-peptide
interaction, that confers susceptibility to DM-mediated
exchange.
There are many fascinating examples of immunoglobulin
superfamily members put to work in a novel ways. But
few, like DM, are altruistic: DM helps out its immediate
class II family with perhaps no chance of binding a
peptide of its own.
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